Kirchhof Paulus, Calkins Hugh
Institute of Cardiovascular Sciences, University of Birmingham, IBR, Room # 136, Birmingham B15 2TT, UK
SWBH and UHB NHS Trusts, Birmingham, UK.
Eur Heart J. 2017 Jan 1;38(1):20-26. doi: 10.1093/eurheartj/ehw260. Epub 2016 Jul 7.
Catheter ablation is increasingly offered to patients who suffer from symptoms due to atrial fibrillation (AF), based on a growing body of evidence illustrating its efficacy compared with antiarrhythmic drug therapy. Approximately one-third of AF ablation procedures are currently performed in patients with persistent or long-standing persistent AF. Here, we review the available information to guide catheter ablation in these more chronic forms of AF. We identify the following principles: Our clinical ability to discriminate paroxysmal and persistent AF is limited. Pulmonary vein isolation is a reasonable and effective first approach for catheter ablation of persistent AF. Other ablation strategies are being developed and need to be properly evaluated in controlled, multicentre trials. Treatment of concomitant conditions promoting recurrent AF by life style interventions and medical therapy should be a routine adjunct to catheter ablation of persistent AF. Early rhythm control therapy has a biological rationale and trials evaluating its value are underway. There is a clear need to generate more evidence for the best approach to ablation of persistent AF beyond pulmonary vein isolation in the form of adequately powered controlled multi-centre trials.
基于越来越多的证据表明与抗心律失常药物治疗相比导管消融术的有效性,越来越多因心房颤动(AF)出现症状的患者接受了导管消融术。目前,约三分之一的房颤消融手术是在持续性或长期持续性房颤患者中进行的。在此,我们回顾现有信息以指导对这些更慢性形式房颤的导管消融。我们确定了以下原则:我们鉴别阵发性和持续性房颤的临床能力有限。肺静脉隔离是持续性房颤导管消融合理且有效的首要方法。其他消融策略正在研发中,需要在对照的多中心试验中进行恰当评估。通过生活方式干预和药物治疗来处理促使房颤复发的并存疾病,应作为持续性房颤导管消融的常规辅助手段。早期节律控制治疗有生物学依据,评估其价值的试验正在进行中。显然需要通过有足够效力的对照多中心试验,为除肺静脉隔离之外的持续性房颤最佳消融方法提供更多证据。